Adjusted difference in the survival between hepatitis B virus and hepatitis C virus related hepatocellular carcinoma by subgroup.

<p>Abbreviation: HBV, hepatitis B virus; HCV, hepatitis C virus; CI, confidence interval; NR, not reached. In each adjusted model, hepatitis B was used as reference for hepatitis C and following variables were adjusted: age, gender, Child-Pugh class, AJCC/mUICC stage, and initial treatment modality.</p><p>Adjusted difference in the survival between hepatitis B virus and hepatitis C virus related hepatocellular carcinoma by subgroup.</p

Long-term survival by etiology.

<p>The median survival was significantly longer in HCV-related HCC patients than in HBV-related HCC patients. (2.17 vs. 1.34 years, <i>P</i><0.01).</p

Characteristics of study population.

<p>Abbreviation: HBV, hepatitis B virus; HCV, hepatitis C virus; S.D, standard deviation; INR, international normalized ratio; AJCC/mUICC, American Joint Committee on Cancer/International Union Against Cancer; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; TACI, transarterial chemoinfusion.</p><p>*These 3 patients received ¹⁶⁶holmium injection therapy. Values are expressed as mean ± standard deviation, median (quartile), or no (%).</p>†<p>BCLC stage and performance status was not collected at the time of data collection. Hence, BCLC stage was re-coded (staged) by authors with Child-Pugh class, tumor size, tumor number and presence of portal vein invasion and extrahepatic spread, without performance status.</p><p>Characteristics of study population.</p

The age-specific incidence rates of hepatocellular carcinoma (HCC) by the etiology (A), by gender in HBV-related HCC (B) and by gender in HCV-related HCC (C).

<p>The annual incidence rates of HBV-related HCC peaked in the 50–59 age group, while the annual incidence rates of HCV-related HCC kept gradually increasing until age ≥70 s. Similar trend was observed after stratified by gender, although the peak mean annual incidence rates was observed in the 50–59 in men and in the 60–69 in women in HBV-related HCC (B). Diamonds (♦) and triangles (▴) represent for HBV and HCV-related HCC in (A), men and women in (B) and (C), respectively.</p

Comparison of prognostic factors between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.

<p>Abbreviation: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio.</p><p>Comparison of prognostic factors between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.</p

Survival by etiology.

<p>Abbreviation: HBV, hepatitis B virus; HCV, hepatitis C virus. HR, hazard ratio. Model 1  =  crude hazard ratio, Model 2  =  adjusted for age, gender, Model 3  =  Model 2 + Child-Pugh class and AJCC/mUICC stage, Model 4  =  Model 3 + initial treatment modality.</p><p>Survival by etiology.</p

Factors associated with survival.

<p>HR, hazard ratio; HBV, hepatitis B virus; AFP, alphafetoprotien.</p><p>Multivariate model included etiology (HBV vs. non-HBV), tumor size, portal vein invasion, extrahepatic spread and AFP levels.</p><p>Factors associated with survival.</p

Baseline characteristics.

<p>^*Initial alphafetoprotein level was missing in 38 patients.</p><p>^†Of the 160 patients with distant metastasis, 33 patients (20.6%) had concomitant nodal metastasis.</p><p>Baseline characteristics.</p

Survival of patients based on the sub-classification.

<p>Patient survival was significantly different based on sub-classification of BCLC stage C patients. Sub-stage C1 includes the patients with portal vein invasion limited to the segmental or sectoral branch and extrahepatic spread limited to the nodal area (black). Sub-stage C2 includes the patients with portal vein invasion that extends beyond the right and/or left main branch without distant metastasis (green), and sub-stage C3 includes the patients with distant metastasis, but portal vein invasion limited to the segmental or sectoral branch (blue). Sub-stage C4 includes the patients with portal vein invasion that extends beyond the right and/or left main branch with distant metastasis (red). ^*<i>P</i> < 0.01.</p

Survival by treatment modalities.

<p>^*Adjusted for age, gender, Child-Pugh class.</p><p>Survival by treatment modalities.</p